Weekly Roundup (Action Alerts PLUS $)
The flow of positive economic data adds to the year-end bullish case.
04:42PM 11/27/09
New Licensing Venture Is a Plus for a Drug Holding (Action Alerts PLUS $)
This remains an HIV story, but new exposure to hep B in Asia will help the company.
10:33AM 11/24/09
Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz
Mipomersen lowers cholesterol but not without liver side effects.
10:56AM 11/17/09
InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz
Safety monitors force change to mid-stage study of ITMN-191
09:11AM 11/17/09
Refiners May Be In for a Ride (RealMoney.com $)
Low inventories expose them to the risks of 'supply shock' or a surge ex-U.S. demand.
09:00AM 11/17/09
Doc Offers Top Hep C Drug Picks: BioBuzz
Vertex, InterMune, Pharmasset get positive reviews after recent Hep C meeting.
01:54PM 11/09/09
Winner in the Pipeline: Under the Radar
Holly Corp. gives investors access to its extremely profitable Holly Energy Partners subsidiary.
05:00AM 11/03/09
Amylin Makes Obesity Drug Deal: BioBuzz
Japanese drugmaker Takeda licenses worldwide rights to Amylin weight-loss pipeline.
12:09PM 11/02/09
GTx CEO Blames FDA for Bone Drug Rejection: BioBuzz
Steiner claims FDA 'moved the goalposts" during acapodene review.
10:08AM 11/02/09
Dendreon Resubmits Provenge to FDA: BioBuzz
The approval decision for the prostate cancer vaccine will probably come in May 2010.
08:56AM 11/02/09
Vertex Hep C Drug Emerges From Weekend Looking Stronger: BioBuzz
Telaprevir is setting a high bar for its Hep C competitors.
07:26AM 11/02/09
Vertex Hep C Drug Cures 80% at New Dose: Study
Data from a phase II study shows telaprevir as safe and effective when twice daily as it is taken thrice daily.
05:30PM 10/31/09
Biotech Mailbag: The Reason(s) for This Selloff
Readers asks why the sector is fading and seek insight on Gilead, Oncothyreon, ImmunoGen and more.
07:00AM 10/30/09
Vertex Hep C Drug Cures Hard-to-Treat Patients
New telaprevir data was released in advance of a big Hep C meeting next week.
07:01AM 10/28/09
Investors Eye Vertex Hep C Competitor: BioBuzz
Is there a Hep C drug which can knock off Vertex's telaprevir?
11:04AM 10/05/09



Connect with TheStreet